Nido Biosciences
Nido Biosciences was a clinical-stage biotech developing NIDO-361 for spinal and bulbar muscular atrophy. The company said it would close in early 2026 after Phase 2 results, according to Fierce Biotech.
The Story
Nido Biosciences was founded in 2020 through 5AM Ventures' 4:59 Initiative to develop treatments for neurological diseases, including spinal and bulbar muscular atrophy (SBMA, also called Kennedy's disease), according to Fierce Biotech.
The company publicly emerged in 2023 with $109 million in financing, Fierce Biotech reported.
NIDO-361 was studied in a global Phase 2 trial for SBMA (ClinicalTrials.gov NCT06411912).
In a company announcement summarized by Fierce Biotech, Nido said the Phase 2 results were not what it had hoped, that NIDO-361 would no longer be a clinical candidate, and that it would close operations in early 2026.
Timeline
Funding
Nido Biosciences raised $109M, as reported in the sources below.
What Happened
Closing early 2026; the company said Phase 2 results meant NIDO-361 would no longer be a clinical candidate